Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Tianjin Multiple Myeloma Active Trials & Centers
As of 2026-10-21, there are 40 active clinical trials for multiple myeloma hosted across 13 tertiary medical centers in Tianjin (including Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS), Tianjin Medical University Cancer Institute and Hospital, Tianjin People's Hospital, etc.).
Participating Medical Centers (13)
Active Studies in Tianjin (40)
Population synthesized by CMDNShowing 0 published English records of 40 registry trials.
All 40 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.